Home > Boards > US Listed > Biotechs >

BioLineRx Ltd. (BLRX)

Add BLRX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/4/2021 4:16:52 AM - Followers: 116 - Board type: Free - Posts Today: 0

BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
BioLineRx also operates BioLine Innovations Jerusalem (BIJ) a biotechnology incubator for the development of pre-clinical therapeutic candidates, and an Early Development Program (EDP) dedicated to identifying and advancing promising early stage programs.



BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to evaluate the effectiveness of BL-7040 for the treatment of inflammatory bowel disease (IBD)

Immediate next steps include evaluating the most advantageous ways to progress with this therapeutic candidate from a clinical and business perspective, including examining potential additional indications. Plans also include accelerating discussions with potential co-development and licensing partners.

BL-8040 (AML) – Received U.S. regulatory approvals to commence a Phase 2a trial for the treatment of relapsed/refractory acute myeloid leukemia (AML); trial to be conducted at three sites in the U.S. and five sites in Israel, with initial patient enrollment expected in Q2 2013; partial results expected in Q4 2013 and final results expected in the second half of 2014

BL-1040 (ventricular remodeling) – Recruitment commenced at U.S. sites for the PRESERVATION I clinical trial, a CE Mark registration trial for BL-1040 (BCM), a novel medical device for the prevention of ventricular remodeling following an acute myocardial infarction; there are currently multiple active sites recruiting in six countries

BL-5010 (skin lesions) – Reached final stages of development for proprietary pen-like applicator for BL-5010, a novel formulation of two acids being developed for the non-surgical removal of skin lesions; planning to commence pivotal CE-Mark registration trial for European approval in the second half of 2013

BL-8020 (HCV) – Commenced a Phase 1/2 clinical trial to evaluate the effectiveness of an orally-available, interferon-free treatment for Hepatitis C (HCV) at two sites in France, following approval from the French regulatory authorities; partial results expected in Q4 2013; final results expected in the first half of 2014

BL-1020 (schizophrenia) – Disappointing results of interim analysis for the Phase 2/3 CLARITY trial led to termination of the trial; full unblinded study data is expected during Q3 2013

BL-9010 (severe asthma) – Added a novel, bi-specific antibody for the treatment of severe and persistent asthma to the main therapeutic pipeline, following promising pre-clinical data

Capital Raise – $8 million direct equity placement to the OrbiMed Group was completed in February 2013

“In the past few months, we have seen major progress on a number of clinical and pre-clinical programs in our pipeline, which offer exciting opportunities to address unmet medical needs in a wide range of therapeutic areas. We believe our active programs offer significant potential for patients around the world, as well as for the future success of our Company and its shareholders,” stated Kinneret Savitsky, Ph.D, Chief Executive Officer of BioLineRx. “In the third quarter of this year, we expect to receive a full analysis of the unblinded study data for all participants in the CLARITY Phase 2/3 trial for BL-1020. While we discontinued this clinical trial in mid-March based on disappointing results of the interim analysis, we will not decide the future of the overall BL-1020 program until we have carried out a more thorough review of the full unblinded results.”

“The PRESERVATION I study being conducted by our partner, Ikaria, for BL-1040, for the treatment of ventricular remodeling post-AMI, is moving forward at full steam, with multiple sites in six countries around the world actively recruiting, including a number of sites in the U.S. BL-1040 remains one of our leading compounds, with significant clinical data expected to be reported next year, and we hope that it will eventually offer a great benefit to heart attack patients,” continued Dr. Savitsky.

“We continue to accelerate development of our clinical pipeline, with three of our compounds completing significant milestones since the beginning of the year. Our BL-7040 compound for IBD completed a Phase 2a open-label, proof-of-concept study with very encouraging and positive results. We are now evaluating next steps for BL-7040 in order to identify the best way to move forward from both a clinical and business perspective, including examining potential additional indications. In parallel, we are also planning to accelerate discussions with potential co-development and licensing partners for this asset.”

“In addition, BL-8040, for hematological cancers, one of our most exciting programs, just received FDA approval to commence a Phase 2a trial for the treatment of relapsed/refractory AML. We are excited to initiate this multicenter, open-label study under an IND, which will be conducted in the U.S. and Israel, and will enroll up to 50 patients. MD Anderson Cancer Center in Houston will be the initial site for this trial, with two additional premier sites in the US and five other well-known sites in Israel expected to participate. We believe the excitement surrounding the trial, especially at these particular sites, is a testament to the need for an AML therapy, as well as the potential of BL-8040 shown in the previous pre-clinical and clinical data.”

“Finally, we recently reported enrollment of the first patient in our Phase 1/2 trial for BL-8020, an oral treatment for HCV, at a leading hospital in Paris, France. We look forward to partial results from the trial in the fourth quarter of 2013, as well as final results in the first half of 2014. I would also like to point out that as our pipeline evolves, we continue to replenish our pre-clinical pipeline with the addition of promising assets, such as BL-9010 for the treatment of severe and persistent asthma, which recently graduated from our Early Development Program,” concluded Dr. Savitsky

Link To Interview with BioLineRX VP Of Business Development:

biolinerx.com -  BioLineRX Website

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BLRX News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 02/26/2021 04:32:25 PM
BLRX News: Notice of Effectiveness (effect) 02/25/2021 06:05:36 AM
BLRX News: Post-effective Amendment to Registration Statement (pos Am) 02/23/2021 09:13:16 AM
BLRX News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 02/23/2021 07:03:05 AM
BLRX News: Annual and Transition Report (foreign Private Issuer) (20-f) 02/23/2021 07:02:06 AM
#2318   3.1700 +0.27 (9.31%) midastouch017 03/04/21 04:16:52 AM
#2317   Risk/ratio seems quite promising, but one has to midastouch017 03/01/21 05:58:55 AM
#2316   just noticed Wainwright adjusts Price target to $22 makingitnow 02/28/21 05:40:48 PM
#2315   Thanks for your post. so early Q2 will makingitnow 02/28/21 04:59:13 PM
#2314   BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 midastouch017 02/23/21 12:55:14 PM
#2313   BioLineRx Reports Year-End 2020 Financial Results and Provides midastouch017 02/23/21 07:19:06 AM
#2311   Thank you I also own PLX. Take a CYDYWinning 02/10/21 02:27:32 AM
#2310   Awesome thank you so much ! I’ll take a CYDYWinning 02/10/21 02:24:30 AM
#2309   BLRX is a make or break stock, midastouch017 02/10/21 02:22:06 AM
#2308   Hi CYDYWinning, midastouch017 02/10/21 02:07:56 AM
#2307   I invested a little of my money here. CYDYWinning 02/10/21 02:05:15 AM
#2306   I tired private messaging you. I’ve followed you CYDYWinning 02/10/21 01:19:53 AM
#2305   Shalom jcon. midastouch017 02/09/21 01:37:41 AM
#2304   Shalom Midas, jcon777 02/08/21 04:35:24 PM
#2303   4.10+0.61 (+17.4785%) midastouch017 02/08/21 12:31:59 PM
#2302   Sometimes that extra fee can be $50 - PennyWorld 02/05/21 07:25:15 AM
#2301   I didn't even look. But this is what BooDog 02/05/21 06:23:53 AM
#2300   BooDog, how much is TD Ameritrade charging for PennyWorld 02/04/21 10:13:52 PM
#2299   2.76 support here, who's ready for round 2? BooDog 01/29/21 12:40:54 PM
#2298   * * $BLRX Video Chart 01-28-2021 * * ClayTrader 01/28/21 06:26:37 PM
#2297   Appreciate Midastouch. glad to see it get some makingitnow 01/28/21 12:38:23 PM
#2296   BioLineRx, Ltd. (BLRX) midastouch017 01/28/21 11:58:21 AM
#2295   come on Baby. Was it just the SA makingitnow 01/28/21 11:40:43 AM
#2294   No sooner said! midastouch017 01/28/21 11:36:38 AM
#2293   Chart starting to set up imo. See BooDog 01/28/21 10:11:06 AM
#2292   BioLineRx: Investors Are About To Cash In On midastouch017 01/28/21 02:08:55 AM
#2291   BioLineRx Announces Closing of $34.5 Million Bought Deal midastouch017 01/23/21 09:10:43 AM
#2290   Nonsens - 1 ADR consists of 15 shares alpamare 01/20/21 09:34:43 AM
#2289   Unless of course: midastouch017 01/20/21 04:24:00 AM
#2288   Wow. This is very toxic deal.. Bottom line Cast Iron 01/20/21 04:15:09 AM
#2287   BioLineRx Announces $10 Million Bought Deal Offering midastouch017 01/20/21 01:25:09 AM
#2286   BioLineRx Increases Previously Announced Bought Deal Offering to midastouch017 01/20/21 01:24:23 AM
#2285   Biotech. midastouch017 01/13/21 07:54:14 AM
#2284   $BLRX breaks through the pivot point. Could BooDog 01/12/21 08:26:59 AM
#2283   Zacks give this company a rating of BUY. makingitnow 01/09/21 02:02:48 PM
#2282   Thank you makingitnow 12/17/20 05:47:48 PM
#2281   Now we just need them and a few BooDog 12/17/20 12:39:06 PM
#2280   BioLineRx down due to 'sell-the-news' reaction to motixafortide midastouch017 12/17/20 01:54:12 AM
#2279   * * $BLRX Video Chart 12-16-2020 * * ClayTrader 12/16/20 05:56:58 PM
#2278   New handle, testing the cup. Guess it BooDog 12/16/20 02:49:28 PM
#2277   New leg up looks to be starting. BooDog 12/16/20 02:42:29 PM
#2276   2020-12-16 18:51:00 GMT DJ BioLine RX Price Target BooDog 12/16/20 02:13:40 PM
#2275   FAR OUT!! lmao BooDog 12/16/20 02:09:11 PM
#2274   H.C. wainwright and CO maintains a buy rating makingitnow 12/16/20 02:06:57 PM
#2273   Wainwright just came out with a $22 PT!!!! maximumgriff 12/16/20 02:00:52 PM
#2272   Time to see if BLRX has what it BooDog 12/16/20 12:27:26 PM
#2271   Chart looking good, RSI cooled nicely as well maximumgriff 12/16/20 11:20:36 AM
#2270   Just need to see these small cup & BooDog 12/16/20 11:09:16 AM
#2269   Steady rise into to close imo maximumgriff 12/16/20 11:02:57 AM
#2268   Long 2.51. eom BooDog 12/16/20 10:55:39 AM
Consent Preferences